Immupharma Share Discussion Threads

[a_2_b] 16/5/2018 23:54

If you look through thursday @ hxxps://autoimmunity.kenes.com/2018/Pages/Interactive-programm.aspx#.Wvy1Jogvy00 you can see tyhe whole breakdown of the program tomorrow:

PL07 PARALLEL SESSION
LUPUS: WHAT IS NEW?

17-May-2018 10:30 12:30


Abstract:
THE P140 PEPTIDE, A HEAT SHOCK PROTEIN INHIBITOR, MODULATES LYSOSOMAL PATHWAYS FOR LUPUS THERAPY
Background
P140/LupuzorTM is a phosphopeptide exhibiting significant protective properties in MRL/lpr lupus-prone mice and patients with SLE. It is currently under evaluation in phase III-clinical trials in the US and Europe.

Method
Various biochemical methods to examine the interaction between P140 and HSPA8 in vitro and in vivo were used.

Results
One of our key findings regarding the P140 mode of action is that in vitro P140 binds and inhibits heat shock proteins HSPA8/HSC70, a chaperone protein that plays important roles in various cellular functions. We show that it decreases HSPA8 expression on gene and protein levels, both in vivo in MRL/lpr mice that received the peptide intravenously, and in vitro, in MRL/N-1 cells, a fibroblast cell line derived from the MRL splenocytes. We discovered also that P140 significantly affects the capacity of HSPA8 to shuttle between cytosol and nucleus upon heat shock. Another important cellular function of HSPA8 is its role in chaperone-mediated autophagy (CMA), a selective autophagic pathway also mediated by chaperones HSP90AA1 and lysosomal receptor LAMP2A. By purifying lysosomes (where P140 accumulates) from the liver and spleen of MRL/lpr mice pre-treated or not with P140, and incubating these lysosomes with CMA substrates, we observed a decrease of intra-lysosome uptake of CMA substrates, confirming in vivo the inhibition effect of P140 on CMA.

Conclusion
The inhibition effect of P140 on HSPA8 is not only important for lupus therapy where HSPA8 has been reported to be overexpressed, but potentially also in other autoinflammatory diseases, including neurological diseases, where modulation of HSPA8 is needed.

Co-authors
F. Wang 1, I. Tasset 2, A.M. Cuervo 2, S. Muller 1
1CNRS- Institut de Biologie Mol£culaire et Cellulaire, Immunopathologie et Chimie Th£rapeutique, Strasbourg, France
2Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, New York, USA

[a_2_b] 16/5/2018 22:44

No problem Sir Brad. Dilly dilly!

[brad44] 16/5/2018 22:00

https://autoimmunity.kenes.com/2018/Documents/Auto%202018%20Preliminary%20Timetable%20-%2010%20April.pdf Check out this linkThanks to a-2-b on lseLupus talk tomorrow 10.30

[lerichman] 16/5/2018 21:15

PJ1: TM is probably a wonderful Chartered Accountant, but way out of his depth as a biopharm Director. I would take anything he says with a grain of salt. The facts as I see them is that this is definitely a drug that works and has a place in the SOC for the treatment of Lupus. The phase 3 trial was underfunded and poorly designed. At this point it will probably cost close to 50 million pouunds to bring this drug to market. The question is whether a partner is willing to invest this sort of money (and probably more) based upon the competitive landscape of other Lupus drugs that will be coming online in the next few years, as well as other opportunities outside of Lupus this potential partner is considering. I happen to believe that someone will find value in this drug and partner with IMM to bring Lupuzor to market, but that is far from a foregone conclusion. But this is also why the stock now sits at 30P. I happen to still be a believer.

[pj 1] 16/5/2018 20:15

Tim Mcarthy Mello 2015 Finncap London

Question. ''What if Phase 3 fails?''

Answer (from Tim McCarthy) ''Then it's game over''

At least he was honest at that point.

[wigwammer] 16/5/2018 19:18

I think there are some people who are statistical hardliners and others who have a more nuanced view. Both perspectives can be persuasive. The point is that if 11 companies are looking, some will have a computer says no attitude based on the headline figures, and others will have a more open minded approach that cares about the detail. You only need a few companies in the latter camp to get competition going for the assets.

[a_2_b] 16/5/2018 18:38

Yeah it's disgusting what a waste of life

[hamila01] 16/5/2018 18:31

wigwammer - And even the posts wanting Lupozor to get to market for the benefit of Lupus sufferers get voted down. There are some complete sickos floating about on this forum....

[wigwammer] 16/5/2018 14:51

I see that post was ticked down. Someone's worried :)

[wigwammer] 16/5/2018 14:47

Yes francisgalton - it is extremely important. What it suggests is that if the lupuzor trial had been designed in the same way as the anifrolumab trial, even with a just n=202, the result would have been positive and statistically significant. That's a pretty fantastic result given that in reality the lupuzor trial was underpowered versus other trials, made no limits to soc dosing and had a large developing market bias which likely skewed the placebo. The point that the extension trial is still running suggests the regulators are keeping an open mind.

[growthinvestor2001] 16/5/2018 14:32

@nobby - Che7win does not feel guilty about anything he does or he would have stopped the ramping posts months ago (he was called out on it enough times).

I just try to ignore him now - hes just posting to wind people up - he has no clue where this is heading and constantly feeling the need to share with us us how pleased he is over 0.5p moves in the share price is getting partcularly tiresome.

Will an RNS please come out and give us something to talk about?..

[rnsday] 16/5/2018 13:53

Nobby you are the biggest tool I have seen on any bb board

[nobbygnome] 16/5/2018 13:05

>> che

Do you feel guilty about not telling anyone before the result that you had serious doubts about the trial design? I am sure all your avid followers are keen to know.

[che7win] 16/5/2018 13:00

But my favourite remains Zimmers comment, ties in harmoniously with Tim and Dimitri proactive interview:"Dr Robert Zimmer MD, PhD, Chief Scientific Officer said: "The study demonstrated that Lupuzor(TM) had a superior response rate over placebo and has an outstanding safety profile. The results in the anti-dsDNA antibody positive group are also encouraging. As we receive further data, we will analyse them and work with our regulatory advisers to agree the optimum way forward."

[nobbygnome] 16/5/2018 12:59

>> che

Do you feel guilty about not telling anyone before the result that you had serious doubts about the trial design? I am sure all your avid followers are keen to know.

[che7win] 16/5/2018 12:58

Someone said this week that they could come out with a positive comment on the drill down and the share would spike.Remember, this is what the company said:"You could have an optimistic scenario where you have conditional approval to make it [Lupuzor] freely available for the patient without having the formal approval. That's the discussion to be had."More than 10 NDAsAt the same time, talks with potential industry partners are ongoing, with more than ten having signed non-disclosure agreements with ImmuPharma. The latest results don't appear to have rattled potential collaborators."

[che7win] 16/5/2018 12:57

So we have a united and positive board, Zimmer, Dimitri, Tim, Muller all very positive.Remember what has been said recently:"Lupuzor is still a potential multi-billion dollar selling drug. The trial hasn't done anything to alter that," said chairman McCarthy."An outside chance this goes to patients, that is the discussions to be had.

[nobbygnome] 16/5/2018 12:55

I try never to be personal but I think any sane, reasonable person will realise what a hypocrite you are after your statement about the trial design earlier today. You really couldn't make it up...

[nobbygnome] 16/5/2018 12:54

>> che

Plus an apology to me would be much appreciated for slagging me off for saying the same thing, when you were thinking it all the time.

TIA

Nobby

[nobbygnome] 16/5/2018 12:50

>> che

Do you feel guilty about not telling anyone before the result that you had serious doubts about the trial design? I am sure all your avid followers are keen to know.

[che7win] 16/5/2018 12:48

I particularly liked Zimmers positivity on the results:"Dr Robert Zimmer MD, PhD, Chief Scientific Officer said: "The study demonstrated that Lupuzor(TM) had a superior response rate over placebo and has an outstanding safety profile. The results in the anti-dsDNA antibody positive group are also encouraging. As we receive further data, we will analyse them and work with our regulatory advisers to agree the optimum way forward."

[bmcb5] 16/5/2018 12:45

maybe a BB without charts at the top would be more appropriate? Then you really can filter all negative thoughts, and tell yourself this is a good investment

[nobbygnome] 16/5/2018 12:43

>> che

Do you feel guilty about not telling anyone before the result that you had serious doubts about the trial design? I am sure all your avid followers are keen to know.

[nobbygnome] 16/5/2018 12:41

>> che

LOL what was the p value on that end point? LOL

[francisgalton] 16/5/2018 12:41

Thank you wigwammer. I have not checked that but if so it is a very important point in Immupharma’s favour.